Welcome to our dedicated page for Can-Fite BioPharma Ltd. news (Ticker: CANF), a resource for investors and traders seeking the latest updates and insights on Can-Fite BioPharma Ltd. stock.
Can-Fite BioPharma Ltd. (CANF) is a clinical-stage biopharmaceutical innovator advancing oral therapies for cancer, liver diseases, and inflammatory conditions through its proprietary A3 adenosine receptor (A3AR) platform. This page serves as your definitive source for official company announcements, clinical trial updates, and strategic developments.
Investors and industry professionals will find curated press releases detailing progress across Can-Fite’s pipeline, including Phase II/III trials for Piclidenoson in psoriasis and Namodenoson’s dual applications in liver cancer and NASH. All content is verified through primary sources to ensure accuracy and timeliness.
Key updates cover regulatory milestones, partnership announcements, and peer-reviewed research findings. The collection emphasizes developments in targeted small molecule therapeutics while maintaining accessibility for both specialist and general audiences.
Bookmark this page to efficiently monitor Can-Fite’s advancements in addressing multi-billion dollar medical markets through its differentiated A3AR approach. Check regularly for critical updates that may influence market positioning and therapeutic innovation.
Can-Fite BioPharma Ltd. (NYSE American: CANF) will be featured in an interview on The RedChip Money Report airing on Bloomberg TV on September 24, 2022, at 7 p.m. ET. CEO Dr. Pnina Fishman will discuss key topics including the Company's Phase 3 trials for Psoriasis and Liver Cancer, and potential $100 million in milestone payments. Can-Fite is advancing therapies in inflammatory, cancer, and liver diseases, with drugs like Namodenoson and Piclidenoson showing promising results in clinical trials. The interview can be accessed in full on Can-Fite’s website.
Can-Fite BioPharma (NYSE American: CANF) announced positive results from the Phase III COMFORT™ study of its psoriasis treatment, Piclidenoson, presented by Dr. Kim Papp at the EADV Congress. The study met its primary endpoint, showing a statistically significant improvement over placebo (p=0.037) at 16 weeks. Piclidenoson demonstrated a safety profile comparable to placebo and better tolerability than Otezla®. The drug is set to progress into a pivotal Phase III registration trial for moderate to severe psoriasis and has shown promise for long-term treatment.
Can-Fite BioPharma Ltd. (NYSE American: CANF) reported financial results for the quarter ending June 30, 2022, showcasing a strong balance sheet with $12.72 million in cash. Key developments include the approval of Namodenoson for compassionate use in Romania and the initiation of a pivotal Phase III study for liver cancer. The Phase III COMFORT trial for psoriasis successfully met its primary endpoint with Piclidenoson. Revenues reached $0.40 million, up 2.7%, while net loss declined to $4.62 million. The company plans to submit registration for Piclidenoson to FDA and EMA.
Can-Fite BioPharma announced that its liver cancer drug Namodenoson has been approved for compassionate use in Romania, showing complete response in at least one patient. The Phase III pivotal study for advanced liver cancer is now open for patient enrollment in multiple countries, including Israel and the U.S. The FDA and EMA have provided regulatory support, and Namodenoson has Orphan Drug and Fast Track status. The liver cancer market is projected to reach $3.8 billion by 2027, reflecting a significant opportunity for Can-Fite.
Can-Fite BioPharma (NYSE: CANF) announced that Dr. Kim A. Papp will present findings from the Phase III COMFORT study at the 31st EADV Congress in Milan on September 10, 2022. The study showed that Piclidenoson significantly improved psoriasis symptoms compared to placebo. Dr. Papp, a leading expert with over 150 studies, is also designing a pivotal Phase III trial for FDA and EMA submission. Can-Fite's drug candidate is positioned to address severe psoriasis, leveraging its unique mechanism of action to inhibit inflammatory cytokines.
Can-Fite BioPharma (NYSE American: CANF) announced the completion of a safety study for Piclidenoson, a treatment for canine osteoarthritis. The efficacy trial will be financed by Vetbiolix, which holds exclusive rights to Piclidenoson for two years. The global market for canine osteoarthritis is anticipated to reach
Can-Fite BioPharma (CANF) plans to submit registration plans for its lead drug Piclidenoson to the FDA and EMA for treating moderate to severe psoriasis. The company reported positive topline results from its Phase III COMFORT study, demonstrating significant improvement over placebo and a favorable safety profile compared to Otezla. Notably, only 1% of Piclidenoson patients experienced gastrointestinal issues, versus 6% for Otezla. The study involved over 400 patients and showed that those with higher disease severity benefited more from Piclidenoson. Can-Fite aims for strong market positioning with this candidate.
Can-Fite BioPharma reports positive results from its Phase III COMFORT™ trial for Piclidenoson, a treatment for moderate to severe plaque psoriasis. The primary endpoint was met, with significant improvement observed in patients receiving a 3 mg dosage compared to placebo at week 16 (9.7% vs. 2.6%, P<0.04). Piclidenoson demonstrated an excellent safety profile, better than Otezla. Can-Fite plans to approach the FDA and EMA for further studies. The company holds five licensing agreements globally for Piclidenoson.
Can-Fite BioPharma (NYSE American: CANF) has announced that their study on CF602, an allosteric modulator of the A3 adenosine receptor, has been published in the journal Andrologia. The study demonstrates that CF602 effectively reverses erectile dysfunction (ED) in a diabetic rat model, showing potential as an alternative treatment for the estimated 30-35% of ED patients who are non-responders to standard PDE5 inhibitors like Viagra and Cialis. The global ED market is valued at $3.6 billion and projected to grow to $5.94 billion by 2028.
Can-Fite BioPharma (NYSE American: CANF) has published an article on A3 Adenosine Receptor-targeting drugs in MDPI's journal Molecules. The data supports the potential of Piclidenoson and Namodenoson as frontrunners for FDA approval, showcasing their efficacy against psoriasis, liver cancer, and NASH. Can-Fite's extensive clinical data involves over 1,500 patients across multiple trials, with current studies including a Phase III for psoriasis and a Phase IIb for NASH. The company has received regulatory designations for its drug candidates that address significant market needs.